# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-20-009203
Filing Date
2020-04-17
Accepted
2020-04-17 17:02:57
Documents
5
Effectiveness Date
2020-04-17

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | nc10006524x2_defa14a.htm | DEFA14A | 39060
2 |  | nc10006524x2_nc1.jpg | GRAPHIC | 2018368
3 |  | nc10006524x2_nc2.jpg | GRAPHIC | 2595827
4 |  | nc10006524x2_nc3.jpg | GRAPHIC | 1411130
5 |  | nc10006524x2_nc4.jpg | GRAPHIC | 445226
| Complete submission text file | 0001140361-20-009203.txt |  | 6889396

Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-34207 | Film No.: 20800406
SIC: 2834 Pharmaceutical Preparations